{"entity":{"id":"nct05257395","kind":"trial","name":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial of XZP-3287 in advanced solid tumours, run by Xuanzhu Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer is a phase 3 interventional study registered as NCT05257395 by Xuanzhu Biopharmaceutical Co., Ltd., with 397 participants enrolled, started 2022-03-14 and due to reach its primary completion in 2025-12-05. Interventions recorded: XZP-3287+ Letrozole/Anastrozole and Placebo + Letrozole/Anastrozole.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05257395","url":"https://clinicaltrials.gov/study/NCT05257395"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["xzp-3287","anastrozole"],"companies":["xuanzhu-biopharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05257395","phase":"3","setting":"A Phase III Study to Evaluate the Efficacy and Safety of XZP-3287 Combined With Letrozole/Anastrozole Versus Placebo Combined With Letrozole/Anastrozole in Patients With HR Positive and HER2 Negative Recurrent/Metastatic Breast Cancer","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","participation":[{"nct":"NCT05257395","source":"https://clinicaltrials.gov/study/NCT05257395","fetchedAt":"2026-10-07T16:53:38.157Z","studySha256":"168fa9cdb9070591b096113f5e7474e5d2afccd753944e9822033e82f06e3dce","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-07-17","leadSponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":397,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2022-03-14","startedType":"actual","enrolled":397,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05257395/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"anastrozole","kind":"drug","name":"Anastrozole","route":"/drugs/anastrozole/"},{"id":"xzp-3287","kind":"drug","name":"XZP-3287","route":"/drugs/xzp-3287/"}],"company":[{"id":"xuanzhu-biopharmaceutical","kind":"company","name":"Xuanzhu Biopharmaceutical","route":"/companies/xuanzhu-biopharmaceutical/"}]}}